{"title":"一名转移性黑色素瘤患者的免疫治疗相关甜味综合征：病例报告","authors":"Rory Barry, Gregg Murray, Sally McGrath, Clive Kilgallen, Karen Eustace","doi":"10.1002/jvc2.445","DOIUrl":null,"url":null,"abstract":"<p>Immunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune-related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metastatic melanoma.</p>","PeriodicalId":94325,"journal":{"name":"JEADV clinical practice","volume":"3 4","pages":"1267-1269"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.445","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy associated Sweet syndrome in a patient with metastatic melanoma: A case report\",\"authors\":\"Rory Barry, Gregg Murray, Sally McGrath, Clive Kilgallen, Karen Eustace\",\"doi\":\"10.1002/jvc2.445\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Immunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune-related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metastatic melanoma.</p>\",\"PeriodicalId\":94325,\"journal\":{\"name\":\"JEADV clinical practice\",\"volume\":\"3 4\",\"pages\":\"1267-1269\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-05-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jvc2.445\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JEADV clinical practice\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.445\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JEADV clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jvc2.445","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Immunotherapy associated Sweet syndrome in a patient with metastatic melanoma: A case report
Immunotherapy agents are now widely used in the treatment of metastatic melanoma. Immune-related adverse events (irAEs) may occur, including cutaneous pathologies in 50% of patients. We report a case of Sweet syndrome (SS) in a patient who was prescribed ipilimumab and nivolumab for metastatic melanoma.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
